Journal of Otolaryngology and Ophthalmology of Shandong University ›› 2019, Vol. 33 ›› Issue (1): 53-58.doi: 10.6040/j.issn.1673-3770.1.2018.040

• Research Progress • Previous Articles     Next Articles

Research progress in the treatment of bronchial asthma with biological agents

Li SHA,Chuanhe LIU*()   

  1. Department of Allergy, Children′s Hospital, Capital Institute of Pediatrics, Beijing 100020, China
  • Received:2018-11-15 Online:2019-01-20 Published:2019-01-28
  • Contact: Chuanhe LIU E-mail:liuchcip@126.com

RichHTML

159

PDF (PC)

1451

Abstract:

Bronchial asthma is a common chronic airway inflammatory disease of the respiratory system. Inhaled corticosteroids are the primary treatment strategy. Studies have shown that the clinical response to inhaled corticosteroids varies due to different types of airway inflammation. A variety of biological agents aimed at inflammatory mediators in airway inflammation have been developed. Randomized controlled trials of these agents have shown that patients with severe eosinophilic asthma benefit from therapy, but controversy remains regarding some aspects of their clinical effects. Their efficacy and safety in children, as well as their long-term effects on disease course and progression need further study and confirmation.

Key words: Asthma, Airway inflammation, Biologic therapy

CLC Number: 

  • R562.2
1 Paul WE , Zhu JF . How are T(H)2-type immune responses initiated and amplified?[J]. Nat Rev Immunol, 2010, 10 (4): 225- 235.
doi: 10.1038/nri2735
2 Harper RW , Zeki AA . Immunobiology of the critical asthma syndrome[J]. Clin Rev Allergy Immunol, 2015, 48 (1): 54- 65.
doi: 10.1007/s12016-013-8407-6
3 Dunn RM , Wechsler ME . Anti-interleukin therapy in asthma[J]. Clin Pharmacol Ther, 2015, 97 (1): 55- 65.
doi: 10.1002/cpt.11
4 Kearley J , Erjefalt JS , Andersson C , et al. IL-9 governs allergen-induced mast cell numbers in the lung and chronic remodeling of the airways[J]. Am J Respir Crit Care Med, 2011, 183 (7): 865- 875.
doi: 10.1164/rccm.200909-1462OC
5 Moro K , Yamada T , Tanabe M , et al. Innate production of T(H)2 cytokines by adipose tissue-associated c-Kit(+)Sca-1(+) lymphoid cells[J]. Nature, 2010, 463 (7280): 540- 544.
doi: 10.1038/nature08636
6 Christianson CA , Goplen NP , Zafar I , et al. Persistence of asthma requires multiple feedback circuits involving type 2 innate lymphoid cells and IL-33[J]. J Allergy Clin Immunol, 2015, 136 (1): 59- 68.e14.
doi: 10.1016/j.jaci.2014.11.037
7 Normansell R , Walker S , Milan SJ , et al. Omalizumab for asthma in adults and children[J]. Cochrane Database Syst Rev, 2014, (1): CD003559.
doi: 10.1002/14651858.CD003559.pub4
8 Storms W , Bowdish MS , Farrar JR . Omalizumab and asthma control in patients with moderate-to-severe allergic asthma: a 6-year pragmatic data review[J]. Allergy Asthma Proc, 2012, 33 (2): 172- 177.
doi: 10.2500/aap.2012.33.3527
9 Long AD , Rahmaoui A , Rothman KJ , et al. Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumab[J]. J Allergy Clin Immunol, 2014, 134 (3): 560- 567.e4.
doi: 10.1016/j.jaci.2014.02.007
10 Gauvreau GM , Arm JP , Boulet LP , et al. Efficacy and safety of multiple doses of QGE031 (ligelizumab) versus omalizumab and placebo in inhibiting allergen-induced early asthmatic responses[J]. J Allergy Clin Immunol, 2016, 138 (4): 1051- 1059.
doi: 10.1016/j.jaci.2016.02.027
11 Bel EH , Wenzel SE , Thompsen PJ , et al. Oral glucocorticoidsparing effect of mepolizumab in eosinophilic asthma[J]. N Ensl Jmed, 2014, 371 (13): 1189- 1197.
doi: 10.1056/NEJMoa1403291
12 Castro M , Zangrilli J , Wechsler ME , et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials[J]. The Lancet Respiratory Medicine, 2015, 3 (5): 355- 366.
doi: 10.1016/S2213-2600(15)00042-9
13 Fitzgerald JM , Bleecker ER , Nair P , et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial[J]. The Lancet, 2016, 388 (10056): 2128- 2141.
doi: 10.1016/S0140-6736(16)31322-8
14 Antoniu SA , Cojocaru I . Pitrakinra for asthma[J]. Expert Opin Biol Ther, 2010, 10 (11): 1609- 1615.
doi: 10.1517/14712598.2010.524203
15 Wenzel S , Wilbraham D , Fuller R , et al. Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies[J]. Lancet, 2007, 370 (9596): 1422- 1431.
doi: 10.1016/S0140-6736(07)61600-6
16 Slager RE , Otulana BA , Hawkins GA , et al. IL-4 receptor polymorphisms predict reduction in asthma exacerbations during response to an anti-IL-4 receptor α antagonist[J]. J Allergy Clin Immunol, 2012, 130 (2): 516- 522.e4.
doi: 10.1016/j.jaci.2012.03.030
17 Vatrella A , Fabozzi I , Calabrese C , et al. Dupilumab: a novel treatment for asthma[J]. J Asthma Allergy, 2014, 7: 123- 130.
doi: 10.2147/JAA.S52387
18 Castro M , Corren J , Pavord ID , et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma[J]. N Engl J Med, 2018, 378 (26): 2486- 2496.
doi: 10.1056/NEJMoa1804092
19 Zayed Y , Kheiri B , Banifadel M , et al. Dupilumab safety and efficacy in uncontrolled asthma: a systematic review and meta-analysis of randomized clinical trials[J]. J Asthma, 2018, 1- 10.
doi: 10.1080/02770903.2018.1520865
20 Corren J , Lemanske RF , Hanania NA , et al. Lebrikizumab treatment in adults with asthma[J]. N Engl J Med, 2011, 365 (12): 1088- 1098.
doi: 10.1056/NEJMoa1106469
21 Piper E , Brightling C , Niven R , et al. A phase Ⅱ placebo-controlled study of tralokinumab in moderate-to-severe asthma[J]. Eur Respir J, 2013, 41 (2): 330- 338.
doi: 10.1183/09031936.00223411
22 Brightling CE , Chanez P , Leigh R , et al. Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial[J]. Lancet Respir Med, 2015, 3 (9): 692- 701.
doi: 10.1016/S2213-2600(15)00197-6
23 Corren J , Parnes JR , Wang LW , et al. Tezepelumab in adults with uncontrolled asthma[J]. N Engl J Med, 2017, 377 (10): 936- 946.
doi: 10.1056/NEJMoa1704064
24 Kirsten A , Watz H , Pedersen F , et al. The anti-IL-17A antibody secukinumab does not attenuate ozone-induced airway neutrophilia in healthy volunteers[J]. Eur Respir J, 2013, 41 (1): 239- 241.
doi: 10.1183/09031936.00123612
25 Busse WW , Holgate S , Kerwin E , et al. Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma[J]. Am J Respir Crit Care Med, 2013, 188 (11): 1294- 1302.
doi: 10.1164/rccm.201212-2318OC
26 O′Byrne PM , Metev H , Puu M , et al. Efficacy and safety of a CXCR2 antagonist, AZD5069, in patients with uncontrolled persistent asthma: a randomised, double-blind, placebo-controlled trial[J]. Lancet Respir Med, 2016, 4 (10): 797- 806.
doi: 10.1016/S2213-2600(16)30227-2
27 Watz H , Uddin M , Pedersen F , et al. Effects of the CXCR2 antagonist AZD5069 on lung neutrophil recruitment in asthma[J]. Pulm Pharmacol Ther, 2017, 45: 121- 123.
doi: 10.1016/j.pupt.2017.05.012
28 Berry MA , Hargadon B , Shelley M , et al. Evidence of a role of tumor necrosis factor alpha in refractory asthma[J]. N Engl J Med, 2006, 354 (7): 697- 708.
doi: 10.1056/NEJMoa050580
29 Howarth PH , Babu KS , Arshad HS , et al. Tumour necrosis factor (TNFalpha) as a novel therapeutic target in symptomatic corticosteroid dependent asthma[J]. Thorax, 2005, 60 (12): 1012- 1018.
doi: 10.1136/thx.2005.045260
30 Erin EM , Leaker BR , Nicholson GC , et al. The effects of a monoclonal antibody directed against tumor necrosis factor-alpha in asthma[J]. Am J Respir Crit Care Med, 2006, 174 (7): 753- 762.
doi: 10.1164/rccm.200601-072OC
31 Taille C . Monoclonal anti-TNF-α antibodies for severe steroid-dependent asthma: a case series[J]. TORMJ, 2013, 7 (1): 21- 25.
doi: 10.2174/1874306401307010021
32 Rouhani FN , Meitin CA , Kaler M , et al. Effect of tumor necrosis factor antagonism on allergen-mediated asthmatic airway inflammation[J]. Respir Med, 2005, 99 (9): 1175- 1182.
doi: 10.1016/j.rmed.2005.02.031
33 Morjaria JB , Chauhan AJ , Babu KS , et al. The role of a soluble TNFalpha receptor fusion protein (etanercept) in corticosteroid refractory asthma: a double blind, randomised, placebo controlled trial[J]. Thorax, 2008, 63 (7): 584- 591.
doi: 10.1136/thx.2007.086314
[1] CAO Zhengyong, LI Xiaobo. Comparison of the safety and efficacy of short-course postoperative topical glucocorticoid adjuvant therapy for eCRSwNP combined with asthma [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2025, 39(2): 43-50.
[2] CHONG Weikun, WANG Juan. Efficacy of Omalizumab in children with moderate and severe allergic asthma and chronic sinusitis [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2024, 38(1): 21-26.
[3] SUN Xiwen, LUO Chunyu, LI Zhipeng, ZHANG Weitian. Role of ferroptosis in inflammatory diseases of the respiratory tract: a review of recent advances [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2023, 37(6): 24-32.
[4] LU Gan, DENG Yuqin, TAO Zezhang. Relationship between allergic diseases and diabetes mellitus and underlying mechanisms [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2023, 37(5): 215-222.
[5] YUAN Yue, FU Shengyao, JIANG Yan, CHEN Min. Research progress of pyroptosis in chronic airway inflammatory disease [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2023, 37(4): 166-171.
[6] WANG Huan, HU Li,YU Hongmeng. Research progress of olfactory dysfunction in chronic rhinosinusitis [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2022, 36(3): 43-49.
[7] WANG Na,CHAI Xiangbin. Research progress on prostate-derived ETS factor in asthma and inflammatory diseases of the nasal mucosa [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2022, 36(3): 136-141.
[8] LI Menghui, ZHI Lili, QI Kaiwen, WANG Shanshan, GAO Qian, BU Meiling,. Clinical research of subcutaneous immunotherapy on children with allergic asthma caused by dust mites and combined with mold allergen [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2022, 36(1): 75-80.
[9] YANG Yifan, CHENG Lei. Rhinosinusitis and asthma in children: united airway disease [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2019, 33(6): 10-15.
[10] Jie SHAO. Problems associated with allergic asthma in children [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2019, 33(1): 25-27.
[11] Chuanhe LIU. The prevalence, diagnosis and management of asthma in children in China [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2019, 33(1): 28-32.
[12] Qianhui QIU,Junxiao GAO. Synchronous control and long-term efficacy of specific immunotherapy for allergic rhinitis and asthma [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2019, 33(1): 33-37.
[13] Hongmeng YU,Zhuofu LIU,Qi DAI. Endoscopic sinus surgery for chronic sinusitis with asthma [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2019, 33(1): 38-41.
[14] Zheng ZHU,Wanjun WANG,Qiurong HU,Jing LI. Allergen inhalation challenge in the research of allergic rhinitis and asthma [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2019, 33(1): 42-48.
[15] Yu ZHANG,Xicheng SONG. Advances in interaction mechanisms and treatment strategy between chronic rhinosinusitis with nasal polyp and asthma [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2019, 33(1): 49-52.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Website Copyright: Editorial Office of Journal of Otolaryngology and Ophthalmology of Shandong University
Address: No.27 Shanda South Road, Jinan, Shandong, China. Post code: 250100 Tel: +86-0531-88366912 Email: ebhxb@sdu.edu.cn Supported by Beijing Magtech Co.Ltd